Conavi Medical Corp. is conducting a public offering of common shares and pre-funded common share purchase warrants, aiming to raise between $12-15 million. The proceeds will be used to obtain US FDA clearance for the next generation Novasight Hybrid system and for general corporate purposes. The offering is expected to close on or about January 13, 2026, subject to regulatory approvals. The company will pay a cash fee to the Agent and grant compensation options. The securities may also be offered via private placement outside of Canada. The A&R Final Prospectus will be accessible on SEDAR+ for more information.

Read more at GlobeNewswire: Conavi Medical Corp. Announces Filing of Amended & Restated